BK0975 Medical Beauty
- 1189.895
- +12.708+1.08%
Huaxi Biotech (688363) 2023 and 2024 first quarter results review: Q1 performance picked up, raw materials and pharmaceutical business growth exceeded expectations
Huaxi Biotech (688363): Skincare adjustments in 23 years dragged down performance, 24Q1 performance surged, and an inflection point appeared
Huaxi Biotech (688363): Strong raw materials+medical terminal business, looking forward to the skincare business returning to a growth trajectory
Huaxi Biotech (688363) Review Report: 23 business adjustments, 24Q1 performance repair and recovery
Huaxi Biotech (688363): 24Q1 performance gradually recovered, looking forward to the results of skincare business adjustments
Huaxi Biotech (688363): The inflection point of Q1 is beginning to show, and we expect skincare products to return to growth after adjustment
Huaxi Biotech (688363): High-quality growth in the medical and aesthetic business, cosmetics actively entered the inflection point of adjustment expectations
Huaxi Biotech (688363) 2023 Report and 2024 Quarterly Report Review: Medical and aesthetic business increases, skincare strategy adjustments reshape potential
Huaxi Biotech (688363): 24Q1 profit inflection point, significant cost reduction and efficiency, expected 618 performance
Huaxi Biotech (688363): Net profit to mother resumed high growth in 24Q1, waiting for adjustments in cosmetics and other businesses to take effect
Amex (300896): The quarterly report is in line with expectations and shows growth resilience
Huaxi Biotech (688363): Q1 performance improved markedly, medical and aesthetic business continued to grow
Aimeike (300896): Performance is in line with expectations, new product releases are expected
Huaxi Biotech (688363): The inflection point in profitability in the first quarter showed leading growth in the medical terminal business
Huaxi Biotech (688363): Q1 surpassed expectations, high medical and aesthetic growth and significant cost reduction
Huaxi Biotech (688363): The 24Q1 deduction of non-net profit exceeds expectations, and the medical and aesthetic inflection point has reached an inflection point where the core focus is on efficacy and skincare adjustments
Huaxi Biotech (688363): The adjustments are showing initial results, but the recovery in performance needs to be further confirmed
Huaxi Biotech (688363): Continued adjustment of skincare products, medical and aesthetic performance picked up markedly in Q1
Huaxi Biotech (688363): 24Q1 profit growth exceeded expectations, profit is expected to continue to recover
Huaxi Biology (688363): First seen the dawn in 1Q24 in 24 years or gradually recovered